While mTOR and TGF‐β signaling inhibitors and drugs targeting metabolic pathways have shown promise in BC therapy,52, 53, 54, 55, 56 their efficacy often encounters challenges such as tumor heterogeneity.29 The gene discussed is TGFB1; the disease is breast cancer.